Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al

• Lisa H Butterfield,
• Hideho Okada,
• Sabine Mueller,
• Zinal S Chheda,
• Bindu Hegde,
• Akane Yamamichi

Affiliations

Lisa H Butterfield

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Hideho Okada

Department of Neurosurgery, UCSF, San Francisco, California, USA

Sabine Mueller

Department of Neurology, UCSF, San Francisco, California, USA

Zinal S Chheda

Sanofi Genzyme, Cambridge, Massachusetts, USA

Bindu Hegde

3T Biosciences Inc, Palo Alto, California, USA

Akane Yamamichi

Department of Neurology, UCSF, San Francisco, California, USA